


ARTICLE

<https://doi.org/10.1038/s41467-019-11395-3>

OPEN

Late-stage peptide C–H alkylation for bioorthogonal C–H activation featuring solid phase peptide synthesis

Alexandra Schischko^{1,2}, Nikolaos Kaplaneris^{1,2}, Torben Rogge¹, Giedre Sirvinskaite¹, Jongwoo Son¹ & Lutz Ackermann¹ 

Methods for the late-stage diversification of structurally complex peptides hold enormous potential for advances in drug discovery, agrochemistry and pharmaceutical industries. While C–H arylations emerged for peptide modifications, they are largely limited to highly reactive, expensive and/or toxic reagents, such as silver(I) salts, in superstoichiometric quantities. In sharp contrast, we herein establish the ruthenium(II)-catalyzed C–H alkylation on structurally complex peptides. The additive-free ruthenium(II)carboxylate C–H activation manifold is characterized by ample substrate scope, racemization-free conditions and the chemoselective tolerance of otherwise reactive functional groups, such as electrophilic ketone, bromo, ester, amide and nitro substituents. Mechanistic studies by experiment and computation feature an acid-enabled C–H ruthenation, along with a notable protodemetalation step. The transformative peptide C–H activation regime sets the stage for peptide ligation in solution and proves viable in a bioorthogonal fashion for C–H alkylations on user-friendly supports by means of solid phase peptide syntheses.

¹Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammannstr. 2, 37077 Göttingen, Germany. ²These authors contributed equally: Alexandra Schischko, Nikolaos Kaplaneris. Correspondence and requests for materials should be addressed to L.A. (email: Lutz.Ackermann@chemie.uni-goettingen.de)

The chemo-selective diversification and ligation of structurally complex peptides^{1–3} is of prime importance in biomolecular chemistry for the modification and assembly of peptides and proteins⁴. Thus, non-natural peptides are paramount to numerous applied areas, ranging from proteomics, diagnostics, and asymmetric syntheses to drug delivery⁵. Likewise, decorated peptides have been identified as increasingly potent therapeutics. Particularly, unnatural amino acids and peptides populate a unique conformational space and feature distinct bioactivities, whereas being stable toward proteolytic enzymes^{6–9}. Thus, the chemo-selective diversification of peptides bears great potential for inter alia medicinal chemistry, synthetic biology, and pharmaceutical industries². As a direct consequence, strategies for the preparation of unnatural amino acids have been devised, for instance, involving asymmetric syntheses¹⁰. Despite the indisputable advances, such approaches largely require pre-functionalized substrates that translate into labor-intensive, multi-step operations, and thereby generate undesired waste products¹¹. Further, cross-couplings between two pre-functionalized substrates are viable under basic reaction conditions. However, also these conventional cross-couplings can lead to the racemization of the peptidic scaffold, and yield stoichiometric amount of undesired byproducts. In response to these limitations, metal-catalyzed C–H activation^{12–18} has emerged as a more atom- and step-economical tool toward decorated peptides^{19–21}, with considerable potential for the late-stage diversification of peptides of relevance to agrochemical and pharmaceutical industries^{22–30}. Thus, peptide C–H arylations have recently witnessed a significant momentum by means of ruthenium^{31,32}, and oxidative bidentate^{33,34} chelation-assisted palladium(II) catalysis, among others^{35–44}. Although these C–H arylation protocols have enabled the synthesis of substituted peptides, they are inherently limited to the introduction of the aryl motif. Furthermore, such arylative approaches require reactive arylidonium and aryldiazonium salts, are operative under

basic conditions or employ stoichiometric quantities of costly and toxic silver(I) salts, thus significantly compromising the step- and atom-economical nature of the C–H activation approach (Fig. 1a).

In sharp contrast, we have now addressed these major shortcomings of C–H functionalization by developing peptide C–H alkylation^{45–48} on structurally complex peptides (Fig. 1b). Notable features of our findings include (i) ruthenium(II)carboxylate-catalyzed^{49–51} peptide C–H alkylation under base-free conditions, (ii) racemization-free amino acid and peptide late-stage diversification, (iii) detailed mechanistic insights into acid-enabled C–H alkylation by experiment and computation, (iv) versatile peptide fluorescence labeling, and (v) chemo-selective peptide ligation in a bioorthogonal fashion. A key asset of our strategy is represented by the peptide C–H alkylation by solid phase peptide synthesis (SPPS)^{52–54}, setting the stage for the operationally simple assembly of structurally complex peptides in an iterative manner on user-friendly resin support.

Results

Establishing C–H activation. We initiated our studies by probing various reaction conditions for the envisioned C–H alkylation of tryptophan **1a** (Table 1). Detailed experimentation indicated aqueous acetic acid to be the solvent of choice (Table 1, entries 1–4). Thereby, basic reaction conditions could be prevented toward a racemization-free hydroarylation regime. The powerful ruthenium(II) catalyst allowed for the site-selective C–H alkylation under mild conditions (Table 1, entries 4–8), which even set the stage C–H functionalization at physiological temperature of only 37 °C (Table 1, entry 9). The robustness of the ruthenium catalysis was reflected by being fully tolerant of H₂O (Table 1, entry 11). It is noteworthy that experimental mechanistic studies unraveled that an acid-enabled facile hydrogen/deuterium exchange with excellent levels of position-selectivity (Fig. 2a),





Fig. 1 C–H alkylation for transformative peptide diversification. **a** Palladium(II/IV) arylation with reactive, expensive, or toxic reagents; **b** versatile peptide C–H alkylation/ligation in solution and on solid support

Table 1 Initial optimization of the C-H alkylation of tryptophan 1a

Entry	Solvent	[1a]	T/°C	Yield/%
1	GVL/HOAc (1/1)	0.3 M	120	58
2	HO ₂ CET	0.3 M	120	35
3	HO ^t iv	0.3 M	120	23
4	HOAc	0.3 M	120	81
5	HOAc	0.3 M	100	88
6	HOAc	0.3 M	80	73
7	HOAc	1.0 M	80	90
8	HOAc	1.0 M	60	80
9	HOAc	1.0 M	37	54
10	HOAc	1.0 M	80	83 ^a
11	HOAc/H ₂ O (3/1)	1.0 M	80	75

Key aspects of C-H alkylation optimization, highlighting acid-enabled C-H activation. Reaction conditions: **1a** (0.15 mmol), **2a** (0.45 mmol), [RuCl₂(*p*-cymene)]₂ (10 mol %), solvent, 15 h ^a[RuCl₂(*p*-cymene)]₂ (5.0 mol %). 2-py: 2-pyridyl

being indicative of an organometallic C-H activation manifold. These features were mirrored by density functional theory (DFT) calculations at the PW6B95-D3(BJ)/def2-QZVP* + SMD (AcOH)//M06-D3/def2-SVP level of theory (Fig. 2b and Supplementary Data set 1). Our computational studies provided strong support for a facile C-H ruthenation, along with a rate-determining protodemetalation by the solvent acetic acid. Furthermore, our detailed DFT analysis highlighted the role of the various η⁶-arene ligands, and the key importance of monocationic ruthenium(II) complexes⁵⁵ as the crucial intermediates for a facile base-assisted internal electrophilic substitution^{56,57} C-H activation, the results of which are described in the Supplementary Fig. 16.

Versatility of peptide C-H activation. With the optimized conditions in hand, we probed the robustness of the ruthenium (II)-catalyzed C-H alkylation regime employing alkenes **2** (Fig. 3a). The C-H alkylation was widely applicable, and the ruthenium(II) catalyst proved tolerant of otherwise reactive functional groups, including fluoro, chloro, bromo, cyano, ester, styrene, thioesters, ketone, and nitro substituents, which are invaluable for post-synthetic manipulation by inter alia olefin metathesis. Likewise, the ruthenium-catalyzed C-H alkylation set




Fig. 2 Ruthenium-catalyzed C-H alkylation for peptide diversification. **a** Experimental evidence for facile C-H cleavage by selective H/D scrambling; **b** Calculated Gibbs free energy profile for the C-H alkylation at the PW6B95-D3(BJ)/def2-QZVP* + SMD(AcOH)//M06-D3/def2-SVP level of theory



a Expedient C–H alkylation *racemization-free***b** Natural products/drug conjugates

Fig. 3 Expedient ruthenium(II)-catalyzed amino-acid C–H alkylation. **a** Ruthenium(II)-catalyzed C–H alkylation with alkenes **2**; **b** ruthenium(II)-catalyzed C–H alkylation for amino-acid conjugates featuring natural products and drugs




Fig. 4 Late-stage functionalization of peptides. Ruthenium(II)-catalyzed C-H alkylation of structurally complex peptides **5** with sensitive functional groups

the stage for the chemo-selective ligation with PEGylated motifs, and enabled position-specific fluorescent labeling. The PEGylation strategy is highly attractive to enhance the solubility and pharmacological properties for drug delivery, and to improve the self-organization and photoluminescent properties of supramolecular nanostructures. The robustness of the developed C-H alkylation

was reflected by the tolerance of free carboxylic acids (**3t** and **3u**), giving rise to useful building blocks. The versatile ruthenium(II) catalysis manifold proved also amenable to sensitive ketones under aqueous conditions. The mild nature of the C-H alkylation allowed here for the use of synthetically-useful Boc-protected amino acids and amino ketones without cleavage of the




Fig. 5 Peptide ligation via C–H functionalization. Ruthenium(II)-catalyzed C–H alkylation, occurring without racemization including β -peptides and twofold C–H activations

sensitive Boc group (**4d** and **4e**, respectively). Moreover, our C–H activation strategy set the stage for the chemo-selective preparation of amino-acid conjugates bearing drugs and natural products, including cholesterol, eugenol, menthol, and ibuprofen (Fig. 3b).

With a robust method for the base-free C–H manipulation of amino acids being established, we next explored the challenging diversification of structurally complex peptides **5** (Fig. 4). Thus, the exceedingly mild modification of peptides proved viable with excellent levels of position- and chemo-selectivities, even on




Fig. 6 Expedient access to functionalized NH-free tryptophan-containing peptides. Traceless removal of the pyridine group under racemization-free conditions

NH-free tryptophan-containing peptides, albeit owing to the peptide solubilities at lower concentrations in select cases. Moreover, various peptides with amino acids bearing coordinating side chains were well tolerated in the ruthenium-catalyzed C–H alkylation. Likewise, the presence of reactive bromoarene moieties did not affect the outcome of the C–H alkylation, being indicative of its complementary nature as compared with typical arylation regimes. Generally, the bioorthogonal, acid-enabled C–H alkylation proceeded without any signs of racemization on the peptidic backbone.

The power of the ruthenium(II) C–H activation manifold was further reflected by the smooth ligation of peptides **5** with engineered peptides **7** (Fig. 5). Hence, substrates **7** derived from the natural amino acids serine and tyrosine were selectively ligated with the tryptophan-derived peptides **5** to furnish the products **8**. Here, the amide and ester moieties in the peptidic backbone were fully tolerated without racemization of the stereogenic centers. In addition, 2-aminoethanol and hydroxyacetic acid were used as enabling linker motifs to provide atom-economical access to the ligated products **8b**, **8e**, **8f**, **8i**, and **8j**. These findings highlight the unique flexibility of the C–H alkylation-based ligation method in that it can be easily adapted to alcohol- or thiol-containing substrates. The judicious choice of an appropriately designed diene linker set the stage for a twofold C–H activation, delivering the double C–H activation/ligation product **8h**, whereas the ibuprofen-derived hybrid **8j** was likewise efficiently accessed by the chemo-selective C–H alkylation strategy. The versatile C–H activation strategy was not limited to α -amino acids. Indeed, our approach enabled the C–H alkylation of β -amino acid-derived peptides as well, thereby providing step-economical access to hexapeptide **8l** with, among others, unprotected serine.

The synthetic utility of our C–H alkylation regime was further demonstrated by the traceless removal of the pyridyl motif to ensure expedient access to NH-free tryptophan-containing peptides (Fig. 6).

Solid phase peptide synthesis peptide C–H alkylation.

Encouraged by the outstanding robustness and chemoselectivity of the bioorthogonal C–H alkylation regime, we probed the peptide C–H alkylation on solid-supported peptides. To this end, we designed the amino acid Fmoc-Trp^{PY}-OH ready for SPPS protocols, which was conveniently incorporated into peptides **10** (Fig. 7 and the Supplementary Information). With the resin-supported peptides in hand, we explored the challenging C–H alkylation to afford the desired functionalized peptides with

excellent levels of chemoselectivity, delivering inter alia arginine and glutamine-containing peptides **12c–e**. Notably, the powerful ruthenium(II)-catalyzed C–H alkylation occurred efficiently on the solid support despite of limited diffusion control. Our approach clearly showcased the key advantages of the on-resin C–H alkylation as to achieving high conversions without compromising the ease of purification. In addition, the challenging C–H activation of poorly soluble peptides and peptide ligation are accomplished by the on-resin approach, whereas jellification and aggregation of peptides during the C–H activation were circumvented through the peptide late-stage diversification strategy on-resin.

Discussion

We have realized a metal-catalyzed peptide C–H alkylation strategy for the racemization-free diversification of peptides in a bioorthogonal manner. Thus, an air- and water-tolerant ruthenium(II) catalyst set the stage for the chemo-selective late-stage diversification of amino acids and peptides. The robustness of the expedient ruthenium(II) catalysis was reflected by C–H modification and ligation of structurally complex peptides. The operationally simple late-stage modification provided direct access to structurally complex molecular architectures and enabled peptide C–H alkylations on resin by solid phase peptide synthesis. These findings should prove invaluable for applications to medicinal chemistry, and biochemistry, illustrating the robust nature of the ruthenium(II)/carboxylate-catalyzed C–H activation for the assembly of engineered molecular architecture. Our report also illustrates the outstanding synthetic utility of ruthenium(II)-catalyzed C–H activation towards complexity-increasing peptide syntheses, which should prove instrumental for fluorescence labeling, late-stage diversifications and peptide ligations in academia as well as in applied areas, including, but not limited to, agrochemical and pharmaceutical industries.

Methods

Ruthenium(II)-catalyzed C–H alkylation of peptides. A 10 mL conical-bottom test tube with a stir bar was charged with py-peptide (30–150 μ mol) and $[\text{RuCl}_2(p\text{-cymene)}]_2$ (10 mol %). Glacial acetic acid (100–300 μ L) and alkene (3.0 equiv) were added. The tube was fitted with a septum and the mixture was heated to 80 °C for 15 h. After cooling to ambient temperature, the reaction mixture was diluted with toluene (1.0–5.0 mL) and purified by column chromatography or preparative thin layer chromatography.

Ruthenium(II)-catalyzed on-resin C–H alkylation of peptides. A 10 mL conical-bottom test tube without a stir bar was charged with a peptide loaded resin (30 μ mol) and $[\text{RuCl}_2(p\text{-cymene)}]_2$ (10.0 mol %). Glacial acetic acid (30–150 μ L) and alkene (3.0–10.0 equiv) were added. The test tube was fitted with a septum and




Fig. 7 C-H functionalization on solid support. On-resin C-H alkylation by user-friendly solid phase peptide synthesis providing access to diversely decorated nona- and decapeptides

the mixture was heated to 80 °C for 15 h with a slight shaking of the reaction vial. After cooling to ambient temperature, the mixture was transferred with methanol to a 10 mL syringe equipped with a frit. The resin was washed with HOAc (5 × 5 mL), MeOH (3 × 5 mL), HOAc (3 × 5 mL), MeOH (3 × 5 mL), and CH₂Cl₂ (5 × 5 mL). After drying overnight at 40 °C, the resin was treated with TFA (3 mL) or TFA/TIS/H₂O/DCM (3 mL, 95:2.5:1.25:1.25) at ambient temperature for 4 h. The cleavage solution was collected and the resin was washed with TFA (3 mL) and HOAc (3 × 5 mL). The combined phases were concentrated under reduced pressure and the peptide was three times precipitated from cold diethyl ether (−20 °C, 5 mL), centrifuged and decanted. The obtained solid was dried under vacuum.

Data availability

All data are also available from the authors upon reasonable request.

Received: 8 August 2018 Accepted: 13 July 2019

Published online: 07 August 2019

References

- Vinogradova, E. V., Zhang, C., Spokoyny, A. M., Pentelute, B. L. & Buchwald, S. L. Organometallic palladium reagents for cysteine bioconjugation. *Nature* **526**, 687–691 (2015).
- Blakemore, D. C. et al. Organic synthesis provides opportunities to transform drug discovery. *Nat. Chem.* **10**, 383–394 (2018).
- Saxon, E. & Bertozzi, C. R. Cell surface engineering by a modified Staudinger reaction. *Science* **287**, 2007–2010 (2000).
- Dawson, P. E., Muir, T. W., Clark-Lewis, I. & Kent, S. B. H. Synthesis of proteins by native chemical ligation. *Science* **266**, 776–779 (1994).
- Davie, E. A. C., Mennen, S. M., Xu, Y. & Miller, S. J. Asymmetric catalysis mediated by synthetic peptide. *Chem. Rev.* **107**, 5759–5812 (2007).
- Rémond, E., Martin, C., Martinez, J. & Cavelier, F. Silicon-containing amino acids: synthetic aspects, conformational studies, and applications to bioactive peptides. *Chem. Rev.* **116**, 11654–11684 (2016).
- Blaskovich, M. A. T. Unusual amino acids in medicinal chemistry. *J. Med. Chem.* **59**, 10807–10836 (2016).
- Xiao, H. et al. Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells. *Angew. Chem. Int. Ed.* **52**, 14080–14083 (2013).
- Chalker, J. M., Bernardes, G. J. L. & Davis, B. G. A “Tag-and-Modify” approach to site-selective protein modification. *Acc. Chem. Res.* **44**, 730–741 (2011).
- Maruoka, K. & Ooi, T. Enantioselective amino acid synthesis by chiral phase-transfer catalysis. *Chem. Rev.* **103**, 3013–3028 (2003).
- Altenbuchner, J., Siemann-Herzberg, M. & Syldatk, C. Hydantoinsases and related enzymes as biocatalysts for the synthesis of unnatural chiral amino acids. *Curr. Opin. Biotechnol.* **12**, 559–563 (2001).
- Park, Y., Kim, Y. & Chang, S. Transition metal-catalyzed C–H amination: scope, mechanism, and applications. *Chem. Rev.* **117**, 9247–9301 (2017).
- Bergman, R. G. Organometallic chemistry: C–H activation. *Nature* **446**, 391–393 (2007).
- Davies, H. M. & Manning, J. R. Catalytic C–H functionalization by metal carbenoid and nitrenoid insertion. *Nature* **451**, 417–424 (2008).
- Hickman, A. J. & Sanford, M. S. High-valent organometallic copper and palladium in catalysis. *Nature* **484**, 177–185 (2012).
- Wencel-Delord, J. & Glorius, F. C–H bond activation enables the rapid construction and late-stage diversification of functional molecules. *Nat. Chem.* **5**, 369 (2013).
- Saint-Denis, T. G., Zhu, R.-Y., Chen, G., Wu, Q.-F. & Yu, J.-Q. Enantioselective C(sp³)-H bond activation by chiral transition metal catalysts. *Science* **359**, pii: eaao4798 (2018).

18. He, J., Wasa, M., Chan, K. S. L., Shao, Q. & Yu, J.-Q. Palladium-catalyzed transformations of alkyl C–H bonds. *Chem. Rev.* **117**, 8754–8786 (2017).
19. Jbara, M., Maity, S. K. & Brik, A. Palladium in the chemical synthesis and modification of proteins. *Angew. Chem. Int. Ed.* **56**, 10644–10655 (2017).
20. Noisier, A. F. & Brimble, M. A. C–H functionalization in the synthesis of amino acids and peptides. *Chem. Rev.* **114**, 8775–8806 (2014).
21. Wang, W., Lorion, M., Shah, J., Kapdi, A. R. & Ackermann, L. Late-stage peptide diversification by position-selective C–H activation. *Angew. Chem. Int. Ed.* **57**, 14700–14717 (2018).
22. Bauer, M., Wang, W., Lorion, M. M., Dong, C. & Ackermann, L. Internal peptide late-stage diversification: peptide-isosteric triazoles for primary and secondary C(sp³)–H activation. *Angew. Chem. Int. Ed.* **57**, 203–207 (2018).
23. Liu, T., Qiao, J. X., Poss, M. A. & Yu, J.-Q. Palladium(II)-catalyzed site-selective C(sp³)–H alkylation of oligopeptides: a linchpin approach for oligopeptide–drug conjugation. *Angew. Chem. Int. Ed.* **56**, 10924–10927 (2017).
24. Ruan, Z., Sauermann, N., Manoni, E. & Ackermann, L. Manganese-catalyzed C–H alkylation: expedient peptide synthesis and modification. *Angew. Chem. Int. Ed.* **56**, 3172–3176 (2017).
25. Chen, G. et al. Ligand-enabled β -C–H arylation of α -amino acids without installing exogenous directing groups. *Angew. Chem. Int. Ed.* **56**, 1506–1509 (2017).
26. Mendive-Tapia, L. et al. Spacer-free BODIPY fluorogens in antimicrobial peptides for direct imaging of fungal infection in human tissue. *Nat. Commun.* **7**, 10940 (2016).
27. Zhu, Y., Bauer, M. & Ackermann, L. Late-stage peptide diversification by bioorthogonal catalytic C–H arylation at 23 °C in H₂O. *Chem. Eur. J.* **21**, 9980–9983 (2015).
28. Chen, G. et al. Ligand-enabled β -C–H arylation of α -amino acids using a simple and practical auxiliary. *J. Am. Chem. Soc.* **137**, 3338–3351 (2015).
29. Mendive-Tapia, L. et al. New peptide architectures through C–H activation stapling between tryptophan–phenylalanine/tyrosine residues. *Nat. Commun.* **6**, 7160–7169 (2015).
30. He, J. et al. Ligand-controlled C(sp³)–H arylation and olefination in synthesis of unnatural chiral α -amino acids. *Science* **343**, 1216–1220 (2014).
31. Schischko, A., Ren, H., Kaplaneris, N. & Ackermann, L. Bioorthogonal diversification of peptides through selective ruthenium(II)-catalyzed C–H activation. *Angew. Chem. Int. Ed.* **56**, 1576–1580 (2017).
32. Arockiam, P. B., Bruneau, C. & Dixneuf, P. H. Ruthenium(II)-catalyzed C–H bond activation and functionalization. *Chem. Rev.* **112**, 5879–5918 (2012).
33. Daugulis, O., Roane, J. & Tran, L. D. Bidentate, monoanionic auxiliary-directed functionalization of carbon–hydrogen bonds. *Acc. Chem. Res.* **48**, 1053–1064 (2015).
34. Rouquet, G. & Chatani, N. Catalytic functionalization of C(sp²)-H and C(sp³)-H bonds by using bidentate directing groups. *Angew. Chem. Int. Ed.* **52**, 11726–11743 (2013).
35. Liu, T., Qiao, J. X., Poss, M. A. & Yu, J. Q. Palladium(II)-catalyzed site-selective C(sp³)–H alkylation of oligopeptides: a linchpin approach for oligopeptide–drug conjugation. *Angew. Chem. Int. Ed.* **56**, 10924–10927 (2017).
36. Subiros-Funosas, R. et al. A Trp-BODIPY cyclic peptide for fluorescence labelling of apoptotic bodies. *Chem. Commun.* **53**, 945–948 (2017).
37. Reay, A. J. et al. Mild and regioselective Pd(OAc)₂-catalyzed C–H arylation of tryptophans by [ArN₂]₂X, promoted by tosic acid. *ACS Catal.* **7**, 5174–5179 (2017).
38. Wang, W., Lorion, M. M., Martinazzoli, O. & Ackermann, L. BODIPY peptide labeling by late-stage C(sp³)–H activation. *Angew. Chem. Int. Ed.* **57**, 13912–13916 (2018).
39. Mendive-Tapia, L. et al. Constrained cyclopeptides: biaryl formation through Pd-catalyzed C–H activation in peptides—structural control of the cyclization vs. cyclodimerization outcome. *Chem. Eur. J.* **22**, 13114–13119 (2016).
40. G. Chen et al. Ligand-enabled C–H arylation of α -amino acids using a simple and practical auxiliary. *J. Am. Chem. Soc.* **137**, 3338–3351 (2015).
41. Tang, J. et al. Peptide-guided functionalization and macrocyclization of bioactive peptidosulfonamides by Pd(II)-catalyzed late-stage C–H activation. *Nat. Commun.* **9**, 3383 (2018).
42. Zhang, X. et al. A general strategy for synthesis of cyclophane-braced peptide macrocycles via palladium-catalyzed intramolecular sp³ C–H arylation. *Nat. Chem.* **10**, 540–548 (2018).
43. Tang, J., He, Y., Chen, H., Sheng, W. & Wang, H. Synthesis of bioactive and stabilized cyclic peptides by macrocyclization using C(sp³)–H activation. *Chem. Sci.* **8**, 4565–4570 (2017).
44. Zhan, B.-B. et al. Site-selective δ -C(sp³)–H alkylation of amino acids and peptides with maleimides via a six-membered palladacycle. *Angew. Chem. Int. Ed.* **57**, 5858–5862 (2018).
45. Rouquet, G. & Chatani, N. Ruthenium-catalyzed *ortho*-C–H bond alkylation of aromatic amides with α,β -unsaturated ketones via bidentate-chelation assistance. *Chem. Sci.* **4**, 2201–2208 (2013).
46. Schinkel, M., Marek, I. & Ackermann, L. Carboxylate-assisted ruthenium(II)-catalyzed hydroarylations of unactivated alkenes via C–H cleavage. *Angew. Chem. Int. Ed.* **52**, 3977–3980 (2013).
47. Murai, S. et al. Efficient catalytic addition of aromatic carbon–hydrogen bonds to olefins. *Nature* **366**, 529–531 (1993).
48. Lewis, L. N. & Smith, J. F. Catalytic carbon–carbon bond formation via *ortho*-metalated complexes. *J. Am. Chem. Soc.* **108**, 2728–2735 (1986).
49. Ackermann, L. Carboxylate-assisted transition-metal-catalyzed C–H bond functionalizations: mechanism and scope. *Chem. Rev.* **111**, 1315–1345 (2011).
50. Ackermann, L., Vicente, R. & Althammer, A. Assisted ruthenium-catalyzed C–H bond activation: carboxylic acids as cocatalysts for generally applicable direct arylations in apolar solvents. *Org. Lett.* **10**, 2299–2302 (2008).
51. Arockiam, P. B., Fischmeister, C., Bruneau, C. & Dixneuf, P. H. C–H bond functionalization in water catalyzed by carboxylate ruthenium(II) systems. *Angew. Chem. Int. Ed.* **49**, 6629–6632 (2010).
52. Noisier, A. F. M., García, J., Ionuț, I. A. & Albericio, F. Stapled peptides by late-stage C(sp³)–H activation. *Angew. Chem. Int. Ed.* **56**, 314–318 (2017).
53. Qin, T. et al. A general alkyl–alkyl cross-coupling enabled by redox-active esters and alkylzinc reagents. *Science* **352**, 801–805 (2016).
54. Merrifield, R. B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. *J. Am. Chem. Soc.* **85**, 2149–2154 (1963).
55. Jiang, Y.-Y., Man, X. & Bi, S. Advances in theoretical study on transition-metal-catalyzed C–H activation. *Sci. China Chem.* **59**, 1448–1466 (2016).
56. Wang, H., Choi, I., Rogge, T., Kaplaneris, N. & Ackermann, L. Versatile and robust C–C activation by chelation-assisted manganese catalysis. *Nat. Catal.* **1**, 993–1001 (2018).
57. Ma, W., Mei, R., Tenti, G. & Ackermann, L. Ruthenium (II)-catalyzed oxidative C–H alkenylations of sulfonic acids, sulfonyl chlorides and sulfonamides. *Chem. Eur. J.* **20**, 15248–15251 (2014).

Acknowledgements

Generous support by the European Research Council under the European Community's Seventh Framework Program (FP7 2007–2013)/ERC Grant agreement no. 307535, the DFG (SPP 1807), and the Onassis Foundation (fellowship to N.K.) is gratefully acknowledged.

Author contributions

A.S., N.K., T.R., G.S., J.S. and L.A. planned, conducted, and analyzed the experiments. T.R. conducted the computational studies. L.A. had the idea for and directed the project. L.A. wrote the manuscript. All authors contributed to discussions.

Additional information

Supplementary Information accompanies this paper at <https://doi.org/10.1038/s41467-019-11395-3>.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

Peer review information: *Nature Communications* thanks Siwei Bi and other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019